Figure 4. DDA inhibited the growth of B16F10 melanoma and TS/A mammary tumours implanted into immunocompetent mice and enhanced animal survival.

Immunocompetent mice were implanted s.c. with (a) B16F10 cells or (b,c) TS/A cells and animals (n=10 mice per group) were treated every 5 days starting on the day of tumour implantation with the indicated doses of either dacarbazine (intraperitoneally (i.p.)), DDA (s.c.), C17 (s.c.), vehicle (s.c.) or Tam (i.p.). Animals were monitored for tumour growth (a,c), *P<0.05; **P<0.01 (analysis of variance (ANOVA), Dunnett’s post test), and survival (b,d), *P<0.05; ***P<0.0001 (log-rank tests). Immunocompetent mice were implanted s.c. with (e) B16F10 cells or (f) TS/A cells, and when the tumour reached a volume of 50–100 mm³, animals (n=10 mice per group) were treated once per day with the indicated doses of dacarbazine (i.p.), DDA (s.c.), C17 (s.c.), vehicle (s.c.) or Tam (i.p.) and were monitored over time for tumour growth, *P<0.05; **P<0.01 (ANOVA, Dunnett’s post tests). The mean tumour volume±s.e.m is shown. The data are representative of three independent experiments.